Scilex Holding Company Depreciation and Amortization
Scilex Holding Company (SCLX) reported Depreciation and Amortization of $5.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-14
- Scilex Holding Company depreciation, depletion and amortization for the quarter ending 2026-06-30 was $2.84M, a 181.09% increase year-over-year.
- Scilex Holding Company depreciation, depletion and amortization for the quarter ending 2026-03-31 was $2.87M, a 186.04% increase year-over-year.
- Scilex Holding Company depreciation, depletion and amortization for the quarter ending 2025-12-31 was $1.59M, a 58.07% increase year-over-year.
- Scilex Holding Company depreciation, depletion and amortization for the quarter ending 2025-09-30 was $1.02M, a 1.79% increase year-over-year.
- Scilex Holding Company depreciation, depletion and amortization for fiscal 2025 was $4.62M, a 14.26% increase from fiscal 2024.
- Scilex Holding Company depreciation, depletion and amortization for fiscal 2024 was $4.05M, a 2.41% decline from fiscal 2023.
- Scilex Holding Company depreciation, depletion and amortization for fiscal 2023 was $4.15M, a 4.67% increase from fiscal 2022.
- Scilex Holding Company depreciation, depletion and amortization for fiscal 2022 was $3.96M, a 4.82% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $5.71M 10-Q · filed 2026-08-14 | $7.29M derived: sum of 3 quarters · filed 2026-08-14 | $8.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.87M 10-Q · filed 2026-05-20 | $4.46M derived: sum of 2 quarters · filed 2026-05-20 | $5.48M derived: sum of 3 quarters · filed 2026-05-20 | $6.49M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $2.61M derived: sum of 2 quarters · filed 2026-04-10 | $3.62M derived: sum of 3 quarters · filed 2026-08-14 | $4.62M 10-K · filed 2026-04-10 |
| 2025-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.03M derived: sum of 2 quarters · filed 2026-08-14 | $3.04M 10-Q · filed 2025-11-14 | $4.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.01M 10-Q · filed 2026-08-14 | $3.02M derived: sum of 3 quarters · filed 2026-08-14 | $4.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-20 | $2.01M derived: sum of 2 quarters · filed 2026-05-20 | $3.01M derived: sum of 3 quarters · filed 2026-05-20 | $4.02M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $2.01M derived: sum of 2 quarters · filed 2026-04-10 | $3.02M derived: sum of 3 quarters · filed 2026-04-10 | $4.05M 10-K · filed 2026-04-10 |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.01M derived: sum of 2 quarters · filed 2025-11-14 | $3.04M 10-Q · filed 2025-11-14 | $4.08M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.04M 10-Q · filed 2025-08-13 | $3.07M derived: sum of 3 quarters · filed 2025-08-13 | $4.11M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-14 | $2.06M derived: sum of 2 quarters · filed 2025-05-14 | $3.10M derived: sum of 3 quarters · filed 2025-05-14 | $4.14M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.07M derived: sum of 2 quarters · filed 2025-03-31 | $3.11M derived: sum of 3 quarters · filed 2025-03-31 | $4.15M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $2.08M derived: sum of 2 quarters · filed 2025-01-17 | $3.11M 10-Q · filed 2025-01-17 | $4.15M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.07M 10-Q · filed 2024-08-13 | $3.11M derived: sum of 3 quarters · filed 2024-08-13 | $4.14M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-13 | $2.07M derived: sum of 2 quarters · filed 2024-05-13 | $3.11M derived: sum of 3 quarters · filed 2024-05-13 | $4.05M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.07M derived: sum of 2 quarters · filed 2024-03-12 | $3.02M derived: sum of 3 quarters · filed 2024-03-12 | $3.96M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.98M derived: sum of 2 quarters · filed 2023-11-14 | $2.93M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $946.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.89M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $944.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $3.78M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $3.78M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |